Application of bufotoxin extract in preparation of medicine for treating human brain glioma

A human brain glioma and extract technology, applied in the field of medicine, can solve the problems of killing human brain glioma cells, easy to recur, difficult to completely resection, etc., to prolong the survival period of tumors, improve brain targeting, The effect of a good dose-response relationship

Inactive Publication Date: 2016-06-22
FOURTH MILITARY MEDICAL UNIVERSITY
View PDF6 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At the beginning of the onset of human glioma, there are usually no typical symptoms, and due to the invasive growth characteristics of glioma located in important functional areas and deep parts, it is difficult to completely cut it, and it is not very sensitive to radiotherapy and

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of bufotoxin extract in preparation of medicine for treating human brain glioma
  • Application of bufotoxin extract in preparation of medicine for treating human brain glioma
  • Application of bufotoxin extract in preparation of medicine for treating human brain glioma

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0032] Experimental example 1 Separation and purification of high-purity bufoginin extract

[0033] Crush the toad venom medicinal material and beat it into a coarse powder with a pulverizer, pass through a 60-mesh sieve, weigh 200g, add 2L of ethanol with a volume concentration of 80%, heat and reflux in a water bath for 2 hours, place it at room temperature, suction filter, and evaporate the filtrate to dryness to obtain crude Extract.

[0034] Weigh 20 g of the crude extract of Bufoni venom, add 200 mL of distilled water, ultrasonically suspend, then add 200 mL of ethyl acetate to repeat the extraction 3 times, combine all the ethyl acetate layers and concentrate to dryness under reduced pressure to obtain the extract. Dissolve the extract in a chloroform-methanol mixture with a volume ratio of 1:1, wherein the quality of the chloroform-methanol mixture is 1.5 times the mass of the extract, filter off the insolubles to obtain a clear solution; add the clear solution while a...

experiment example 2

[0036] Experimental Example 2 Preparation of Bufagenin Nanostructured Lipid Carrier

[0037] Prescription: (by weight ratio) In this experimental example, the extract of toad venom prepared in Experimental Example 1 was used.

[0038]

[0039] Preparation process: Weigh the prescribed amount of lipid material and toad venom extract, put them in a 75°C water bath and heat them with magnetic stirring to dissolve, and obtain a transparent and uniform oil phase; add the prescribed amount of LipoidE80?, PluronicF68 and sodium deoxycholate to an appropriate amount of water for injection , heated to 75°C under 500rpm magnetic stirring, dispersed and dissolved to obtain the water phase; under magnetic stirring, the water phase was added dropwise to the oil phase at the same temperature while it was hot, magnetically stirred for 5 minutes, then ultrasonically dispersed for 10 minutes, cooled in an ice-water bath under stirring conditions, Under sterile conditions, sterilize by filtr...

experiment example 3

[0040] Preparation of Experimental Example 3 Bufagenin Submicroemulsion Preparation

[0041] Prescription: (by weight ratio) In this experimental example, the extract of toad venom prepared in Experimental Example 1 was used.

[0042]

[0043] Preparation process: Weigh the prescribed amount of medium-chain triacylglycerol and long-chain triacylglycerol, add LipoidE80? and toad venom extract in sequence, heat and stir at 75°C for 30 minutes until dissolved, and obtain a clear drug-containing oil phase; PluronicF68, sodium oleate and glycerin were added to an appropriate amount of water for injection, heated and stirred at 70°C to dissolve to obtain the water phase; under the stirring of a high-speed disperser at 12,000 rpm, the oil phase was slowly added to the water phase, and continued to stir for 3 minutes to prepare to obtain colostrum; colostrum with 0.1mol L -1 Adjust the pH value of hydrochloric acid solution to 6.0, dilute to 100mL with water for injection, cool, t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
Login to view more

Abstract

The present invention discloses the application of toad venom extract containing more than 90% of bufolin, cinobufagin and cinobufagin in the preparation of medicines for treating human glioma. The content ratio of tobafagenin is 2:3:5, and the extract of toad venom is prepared into a nano-preparation. The bufagenin nano-preparation of the invention can increase the distribution of bufagenin in the brain and avoid being taken up by the heart, thereby improving the brain-targeting property of the drug and reducing cardiotoxicity. Compared with the common extract solution of bufogenin, the nano-preparation of bufogenin has a stronger therapeutic effect on glioma brain and less side effects, thus enhancing the use value of bufogenin and providing a new method for the treatment of glioma. new drug.

Description

technical field [0001] The invention relates to the application of a nano-preparation based on toad venom extract in the preparation of medicines for treating human brain glioma, and belongs to the technical field of medicine. Background technique [0002] Human glioma is the most common primary brain tumor arising from the canceration of glial cells in the brain and spinal cord, accounting for about 35% to 61% of intracranial tumors. It is highly invasive and has a poor prognosis. Malignant tumors with high mortality and disability rates. At the beginning of the onset of human glioma, there are usually no typical symptoms, and due to the invasive growth characteristics of glioma located in important functional areas and deep parts, it is difficult to completely cut it, and it is not very sensitive to radiotherapy and chemotherapy, and it is very easy to relapse . However, chemical drugs and general anti-tumor traditional Chinese medicines are difficult to simultaneously k...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K35/65A61P35/00A61K31/585
CPCA61K35/65A61K9/1075A61K9/127A61K31/585A61K47/34A61K2300/00
Inventor 翁琰王艳华文爱东奚苗苗杨志福段佳林卫国
Owner FOURTH MILITARY MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap